A new type of single-dose vaccine comes in a nasal spray and doesn't require refrigeration.

The latest design and testing of these "nanovaccines" sets the stage to dramatically alter the public health landscape because it can get more people vaccinated around the world squash the looming threats of emerging and re-emerging diseases. 

Balaji Narasimhan, Ph.D., the project's lead researcher who presented the work at the National Meeting&Exposition of the American Chemical Society, noted that most of today's vaccines require needles, boosters and refrigeration, all of which pose challenges for doctors and patients.

Researchers are developing spray “nanovaccines” that don’t require refrigeration, an advantage for people in remote areas.  Credit:Jakub Jirsák/iStock/Thinkstock

Other than the pain factor, which can lower the chances that someone will seek out a vaccine, follow-up shots and refrigeration further reduce the reach of these vitally important preventive treatments. In some places with limited resources, refrigeration simply isn't available. Thus, many people who need vaccinations the most aren't getting them at all. The good news is that the vaccines Narasimhan's team is developing don't need to be kept cold and are easy to administer.

"Our nanovaccines can be stored at room temperature for as long as six to 10 months and still work," said Narasimhan, professor of chemical engineering at Iowa State University. "Also, we're designing them so they get delivered in one dose through a nasal spray, which could potentially allow patients to give the vaccine to themselves."

Another major limitation of traditional vaccines is the way they work, he said. Most current vaccines help a person develop disease immunity by introducing part of a virus or bacteria and triggering the body's humoral response — the part of the immune system that produces antibodies to fight off a harmful pathogen. Later, if the person gets infected by that microbe, the body immediately knows how to respond.

But increasingly, evidence is emerging that the other component of the body's immune system, what's called the cell-mediated arm, also plays an important part in some emerging and re-emerging diseases, such as whooping cough. This side of the immune system depends on a group of cells called T cells, rather than antibodies, to fight viruses and bacteria.

Part of the elegance of these nanovaccines is their simplicity and versatility, Narasimhan explained. They are made of only two components: bits of proteins from a virus or bacteria packed into nontoxic, biodegradable polymers that can be custom-designed.

When administered through the nose or by a shot, these tiny packages enter the body and flag the immune system. Sentinels called antigen-presenting cells that keep watch in the body for foreign invaders gobble up the nanovaccine particles, chop up the polymers and pathogen proteins, and appropriately put pieces of the proteins on their surfaces. Depending on the chemistry of the nanovaccine, this triggers the body's cell-mediated or humoral immune response and trains it to recognize the pathogen and attack it quickly in case of future infections.

"We have exciting results that attest to the ability of the nanovaccine formulations to do a very good job of activating cell-mediated immunity," said Narasimhan. "We've shown that it works with rodents, and we're moving forward to show that in larger animals, as well."

Source: "No-refrigeration, spray vaccine could curb diseases in remote areas" - ACS meeting.